Empagliflozin Shows Promise As An Adjunct To Selective Serot

Empagliflozin Shows Promise As An Adjunct To Selective Serotonin Reuptake Inhibitors In Reducing Symptom Severity In Major Depressive Disorder

1. Combination therapy of empagliflozin and citalopram reduced symptom severity in patients with major depressive disorder. 2. This average reduction in symptom severity was statistically significant over time in comparison to the reduction of symptoms seen in the placebo-citalopram group. Evidence Rating Level: 1 (Excellent) Antidepressants like selective serotonin reuptake inhibitors (SSRIs) are presently first-line

Related Keywords

, Minute Medicine Inc , Rating Level , Hamilton Depression Rating Scale , Escitalopram , Depression , Empagliflozin , Mmdd , Sglt2 , Psychiatry , Wellness ,

© 2025 Vimarsana